New Product For Pfizer Specialty Takes Pulmonary Arterial Hypertension To Heart
July 2nd, 2009 by samospsipsi
Pfizer Australia announced that it has signed an agreement to acquire the local distribution rights for THELIN® (Sitaxentan sodium), an oral, once-daily highly selective endothelin receptor antagonist, indicated for the treatment of pulmonary arterial hypertension (PAH) in patients with NYHA/WHO Functional Class III symptoms to improve exercise ability. Efficacy has been shown in primary pulmonary hypertension and in pulmonary hypertension associated with connective tissue disease1.
More: continued here
